ACR-2316 is a selective WEE1/PKMYT1 inhibitor ... known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial, focusing ...

The WEE1/PKMYT1 inhibitor is currently in a phase ... Lilly had later picked up the CHK1/2 inhibitor before discarding it in 2019 after phase 2 studies didn't show enough promise.

This clinical collaboration aims to explore the synergy between Debio 0123, a potential best-in-class, brain-penetrant, and highly selective WEE1 inhibitor, and lunresertib, a first-in-class ...

“Combining with Debiopharm’s highly selective WEE1 inhibitor is the ideal strategy to further extend our leadership in PKMYT1 inhibitor development,” said Lloyd M. Segal, CEO of Repare.

Collaborative clinical study will investigate a novel combination of Debio 0123, Debiopharm’s potent, brain penetrant inhibitor of WEE1, and lunresertib, Repare Therapeutics’ first-in-class PKMYT1 ...

This novel dual WEE1/PKMYT1 inhibitor has the potential to ... a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial across multiple tumor ...

a dual WEE1 and PKMYT1 inhibitor. The company plans to prioritize Investigational New Drug (IND) enabling studies for ACR-2316 to be ready for IND submission by the fourth quarter of 2024.